Authors
Latest:
Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural MetastasesEstelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Darolutamide/ADT Yields OS Benefit in mHSPC Across All Disease VolumesFindings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.
Latest:
Ferdinandos Skoulidis, MD, PhD, MRCP, Discusses Exciting Research in the Lung Cancer Field From ASCO 2021Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
Latest:
A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity ReactionStacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.
Latest:
Input From a Multidisciplinary Team of Medical Providers is ‘Necessary’ to Manage Contralateral Breast Cancer, Says ExpertIt takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
Latest:
Non-BCMA Targeting Bispecifics in MM and Future Directions in CareBefore closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
Latest:
Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific TherapyPanelists discuss how to approach treatment decisions and management strategies for a 58-year-old woman with relapsed/refractory multiple myeloma who is post-autologous stem cell transplant, MRD-negative, and currently receiving bispecific antibody therapy, considering factors such as prior treatments, response duration, and long-term treatment goals.
Latest:
Practice Pearls for Optimizing the Management of Advanced RCCExperts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.
Latest:
Guidelines for Opioid Use in Cancer Management are Needed, Expert SaysAlthough opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Latest:
Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related InfectionsA retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From EndometriosisLearn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Latest:
Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple MyelomaA Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Multiprong Leukemia Efforts Boost the Atlantic Health System Heme/Onc ProgramAn upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
